National Lipid Association Annual Summary of Clinical Lipidology 2016

Journal of Clinical Lipidology

Volumn 10, Issue 1, 2016, Pages S1-S43

  Bays, Harold E ^a   Jones, Peter H ^b   Orringer, Carl E ^c   Brown, W Virgil ^d   Jacobson, Terry A ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Annual Summary; Cholesterol; Clinical Lipidology; Dyslipidemia; Guidelines; National Lipid Association; Recommendations

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; DEXTRAN SULFATE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

APHERESIS; BARIATRIC SURGERY; BODY WEIGHT CONTROL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DIET THERAPY; DISEASE CLASSIFICATION; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOLIPEMIA; INFLAMMATION; INTERMEDIATE RISK PATIENT; LIPID ANALYSIS; LOW RISK PATIENT; MEDICAL SOCIETY; METABOLIC SYNDROME X; OBESITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ANIMAL; COMPLICATION; DRUG EFFECTS; DYSLIPIDEMIAS; GENETICS; LIPID METABOLISM; METABOLISM;

ANIMALS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS;

EID: 84966307899     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.08.002     Document Type: Review

References (205)

1. Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary. J Clin Lipidol 8 (2014), 473–488.
2. Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol 9 (2015), 129–169.
3. Ramjee, V., Sperling, L.S., Jacobson, T.A., Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 58 (2011), 457–463.
4. Pencina, M.J., D'Agostino, R.B., Zdrojewski, T., et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol 22 (2015), 1321–1327.
5. Sniderman, A.D., Lamarche, B., Contois, J.H., de Graaf, J., Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 25 (2014), 461–467.
6. Brown, W.V., Breslow, J., Ballantyne, C., Clinical use of genetic typing in human lipid disorders. J Clin Lipidol 6 (2012), 199–207.
7. Yuan, G., Al-Shali, K.Z., Hegele, R.A., Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176 (2007), 1113–1120.
8. Hooper, A.J., Burnett, J.R., Update on primary hypobetalipoproteinemia. Curr Atheroscler Rep, 16, 2014, 423.
9. Welty, F.K., Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 25 (2014), 161–168.
10. Youngblom, E., Knowles, J.W., Familial Hypercholesterolemia. Pagon, R.A., Adam, M.P., Ardinger, H.H., (eds.) GeneReviews® [Internet], 2014, University of Washington, Seattle, Seattle (WA), 1993–2015 Available at: http://www.ncbi.nlm.nih.gov/books/NBK174884/.
11. Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35 (2014), 2146–2157.
12. Bays, H., McKenney, J., Davidson, M., Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 3 (2005), 789–820.
13. Fasano, T., Sun, X.M., Patel, D.D., Soutar, A.K., Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 203 (2009), 166–171.
14. Ito, M.K., McGowan, M.P., Moriarty, P.M., National Lipid Association Expert Panel on Familial H. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), S38–45.
15. Goldberg, A.C., Hopkins, P.N., Toth, P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), 133–140.
16. Hopkins, P.N., Toth, P.P., Ballantyne, C.M., Rader, D.J., National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), S9–17.
17. Robinson, J.G., Goldberg, A.C., National Lipid Association Expert Panel on Familial H. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5 (2011), S18–29.
18. Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490a.
19. Watts, G.F., Gidding, S., Wierzbicki, A.S., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb 21 (2014), 368–374.
20. Austin, M.A., Hutter, C.M., Zimmern, R.L., Humphries, S.E., Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 160 (2004), 407–420.
21. Haase, A., Goldberg, A.C., Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol 23 (2012), 282–289.
22. Williams, R.R., Hunt, S.C., Schumacher, M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72 (1993), 171–176.
23. Raal, F.J., Honarpour, N., Blom, D.J., et al., TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 341–350.
24. Bays, H.E., Toth, P.P., Kris-Etherton, P.M., et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol 7 (2013), 304–383.
25. Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 5 (2011), 338–367.
26. Toth, P.P., Barter, P.J., Rosenson, R.S., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 7 (2013), 484–525.
27. Rosenson, R.S., Brewer, H.B. Jr., Ansell, B., et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128 (2013), 1256–1267.
28. Rosenson, R.S., Brewer, H.B. Jr., Davidson, W.S., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125 (2012), 1905–1919.
29. Brown, W.V., Ansell, B.J., Mackey, R.H., Toth, P.P., JCL Roundtable: HDL in the primary care setting. J Clin Lipidol 8 (2014), 364–372.
30. Brown, W.V., Brewer, H.B., Rader, D.J., Schaefer, E.J., HDL as a treatment target. J Clin Lipidol 4 (2010), 5–16.
31. Brown, W.V., Ballantyne, C.M., Jones, P.H., Marcovina, S., Management of Lp(a). J Clin Lipidol 4 (2010), 240–247.
32. Toth, P.P., Grabner, M., Punekar, R.S., Quimbo, R.A., Cziraky, M.J., Jacobson, T.A., Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis 235 (2014), 585–591.
33. Jacobson, T.A., Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 88 (2013), 1294–1311.
34. Tsimikas, S., Hall, J.L., Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 60 (2012), 716–721.
35. Nordestgaard, B.G., Chapman, M.J., Ray, K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31 (2010), 2844–2853.
36. Bonaa, K.H., Njolstad, I., Ueland, P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006), 1578–1588.
37. Ntaios, G., Savopoulos, C., Grekas, D., Hatzitolios, A., The controversial role of B-vitamins in cardiovascular risk: An update. Archives of cardiovascular diseases 102 (2009), 847–854.
38. Robinson, J.G., Wang, S., Jacobson, T.A., Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 110 (2012), 1468–1476.
39. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2013 May;59(5):752-70. doi: 10.1373/clinchem.2012.196733. Epub 2013 Feb 5. Erratum in: Clin Chem. 2013 Aug;59(8):1275.
40. Otvos, J.D., Mora, S., Shalaurova, I., Greenland, P., Mackey, R.H., Goff, D.C. Jr., Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5 (2011), 105–113.
41. Cromwell, W.C., Otvos, J.D., Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 98 (2006), 1599–1602.
42. Kathiresan, S., Otvos, J.D., Sullivan, L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006), 20–29.
43. Bays, H., Conard, S., Leiter, L.A., et al. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids Health Dis, 9, 2010, 136.
44. Kostner, K.M., Marz, W., Kostner, G.M., When should we measure lipoprotein (a)?. Eur Heart J 34 (2013), 3268–3276.
45. Ridker, P.M., Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?. Current atherosclerosis reports, 15, 2013, 295.
46. Athyros, V.G., Kakafika, A.I., Karagiannis, A., Mikhailidis, D.P., Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 200 (2008), 1–12.
47. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.
48. Jacobson, T.A., Maki, K.C., Orringer, C., et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 9:6 suppl 1 (2015), S1–S121.
49. Scherer, J., Singh, V.P., Pitchumoni, C.S., Yadav, D., Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol 48 (2014), 195–203.
50. Tenner, S., Baillie, J., DeWitt, J., Vege, S.S., American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 108 (2013), 1400–1415 1416.
51. Nogueira, J.P., Maraninchi, M., Béliard, S., et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 32 (2012), 1039–1044.
52. Singh, N., Sharma, B., Sharma, M., et al. Evaluation of early enteral feeding through nasogastric and nasojejunal tube in severe acute pancreatitis: a noninferiority randomized controlled trial. Pancreas 41 (2012), 153–159.
53. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl 2 (2014), S76–S99.
54. Dattilo, A.M., Kris-Etherton, P.M., Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56 (1992), 320–328.
55. Roussell, M.A., Kris-Etherton, P., Effects of lifestyle interventions on high-density lipoprotein cholesterol levels. J Clin Lipidol 1 (2007), 65–73.
56. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129:25 Suppl 2 (2014), S102–S138.
57. Millen, B.E., Wolongevicz, D.M., de Jesus, J.M., Nonas, C.A., Lichtenstein, A.H., 2013 American Heart Association/American College of Cardiology Guideline on Lifestyle Management to Reduce Cardiovascular Risk: practice opportunities for registered dietitian nutritionists. J Acad Nutr Diet 114 (2014), 1723–1729.
58. LaForge, R., Exercise and blood lipid disorders. Briant, C., (eds.) ACE Medical Exercise Specialist Manual, 2015, American Council on Exercise, San Diego, 208–243.
59. Durstine, J.L., Grandjean, P.W., Davis, P.G., Ferguson, M.A., Alderson, N.L., DuBose, K.D., Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med 31 (2001), 1033–1062.
60. Kelley, G.A., Kelley, K.S., Franklin, B., Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil 26 (2006), 131–139 quiz 140-131, discussion 142–134.
61. Kelley, G.A., Kelley, K.S., Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. Public health 121 (2007), 643–655.
62. Kraus, W.E., Slentz, C.A., Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect. Obesity (Silver Spring) 17:Suppl 3 (2009), S21–26.
63. Magkos, F., Basal very low-density lipoprotein metabolism in response to exercise: mechanisms of hypotriacylglycerolemia. Prog Lipid Res 48 (2009), 171–190.
64. Paoli, A., Pacelli, Q.F., Moro, T., et al. Effects of high-intensity circuit training, low-intensity circuit training and endurance training on blood pressure and lipoproteins in middle-aged overweight men. Lipids Health Dis, 12, 2013, 131.
65. Seron, P., Lanas, F., Pardo Hernandez, H., Bonfill Cosp, X., Exercise for people with high cardiovascular risk. Cochrane Database Syst Rev(8), 2014, CD009387.
66. Honda, T., Chen, S., Kishimoto, H., Narazaki, K., Kumagai, S., Identifying associations between sedentary time and cardio-metabolic risk factors in working adults using objective and subjective measures: a cross-sectional analysis. BMC Public Health, 14, 2014, 1307.
67. Slentz, C.A., Houmard, J.A., Kraus, W.E., Modest exercise prevents the progressive disease associated with physical inactivity. Exerc Sport Sci Rev 35 (2007), 18–23.
68. Slentz, C.A., Aiken, L.B., Houmard, J.A., et al. Inactivity, exercise, and visceral fat. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol (1985) 99 (2005), 1613–1618.
69. Seger JC, Horn DB, Westman EC, Primack C, Long J, Clark T, McCarthy W, Bays HE. Obesity Algorithm, presented by the Obesity Medicine Association. 2015-2016. Available at: www.obesityalgorithm.org. Accessed February 2, 2016.
70. Landsberg, L., Aronne, L.J., Beilin, L.J., et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment–a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 21 (2013), 8–24.
71. Bays, H., Adiposopathy, “Sick Fat,” Ockham's Razor, and Resolution of the Obesity Paradox. Curr Atheroscler Rep, 16, 2014, 409.
72. Bays, H., Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 21 (2014), 345–351.
73. Volek, J.S., Phinney, S.D., Forsythe, C.E., et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids 44 (2009), 297–309.
74. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice 1 Guideline. Available at: http://press.endocrine.org/doi/abs/10.1210/jc.2014-3415. Accessed February 19, 2016.
75. Bostwick, J.M., A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc 85 (2010), 538–550.
76. Hasnain, M., Vieweg, W.V., Hollett, B., Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 124 (2012), 154–167.
77. Hasnain, M., Vieweg, W.V., Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 125 (2013), 117–129.
78. Perez-Iglesias, R., Crespo-Facorro, B., Martinez-Garcia, O., et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 99 (2008), 13–22.
79. Leucht, S., Cipriani, A., Spineli, L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
80. Sjostrom, L., Narbro, K., Sjostrom, C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
81. Sjostrom, L., Lindroos, A.K., Peltonen, M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
82. Stone, N.J., Robinson, J., Lichtenstein, A.H., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
83. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994 Nov 19), 1383–1389.
84. Cannon, C.P., Braunwald, E., McCabe, C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine 350 (2004), 1495–1504.
85. de Lemos, J.A., Blazing, M.A., Wiviott, S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004), 1307–1316.
86. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine 352 (2005), 1425–1435.
87. Pedersen, T.R., Faergeman, O., Kastelein, J.J., et al. Highdose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005), 2437–2445.
88. Cannon, CP, Blazing, MA, Giugliano, RP, et al., IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372:25 (2015 Jun 18), 2387–2397.
89. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 8 (2014), 29–60.
90. Anderson, T.J., Gregoire, J., Hegele, R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29 (2013), 151–167.
91. Teramoto, T., Sasaki, J., Ishibashi, S., et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan–2012 version. J Atheroscler Thromb 20 (2013), 850–860.
92. European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (2011), 1769–1818.
93. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
94. Grundy, S.M., Cleeman, J.I., Merz, C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004), 227–239.
95. Maki, K.C., Bays, H.E., Dicklin, M.R., Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 6 (2012), 413–426.
96. Bays, H., Rhyne, J., Abby, S., Lai, Y.L., Jones, M., Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 22 (2006), 2191–2200.
97. Guyton, J.R., Bays, H.E., Grundy, S.M., Jacobson, T.A., An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8 (2014), S72–81.
98. Ganga, H.V., Slim, H.B., Thompson, P.D., A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168 (2014), 6–15.
99. Rosenson, R.S., Baker, S.K., Jacobson, T.A., Kopecky, S.L., Parker, B.A., An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S58–71.
100. Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S47–57.
101. Rojas-Fernandez, C.H., Goldstein, L.B., Levey, A.I., Taylor, B.A., Bittner, V., An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S5–16.
102. Maki, K.C., Ridker, P.M., Brown, W.V., Grundy, S.M., Sattar, N., An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S17–29.
103. Swerdlow, D.I., Sattar, N., A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. Diabetologia 57 (2014), 2433–2435.
104. Kellick, K.A., Bottorff, M., Toth, P.P., A clinician's guide to statin drug-drug interactions. J Clin Lipidol 8 (2014), S30–46.
105. Oates, J.A., Chapter 5. The science of drug therapy. Brunton, L.L., (eds.) Goodman and Gilman's the pharmacologic basis of therapeutics - 11th edition (2006), 2006, Medical Publishing Division, McGraw-Hill, 117–136.
106. Group, S.C., Link, E., Parish, S., et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359 (2008), 789–799.
107. Lennernas, H., Clinical pharmacokinetics of atorvastatin. Clinical pharmacokinetics 42 (2003), 1141–1160.
108. Gerber, J.G., Rosenkranz, S.L., Fichtenbaum, C.J., et al., AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 39 (2005), 307–312.
109. Brown, W.V., Brook, R., Hemphill, L.C., Moriarty, P.M., The use of lipopheresis in the practice of clinical lipidology. J Clin Lipidol 6 (2012), 98–104.
110. Moriarty, P.M., Hemphill, L., Lipoprotein apheresis. Cardiol Clin 33 (2015), 197–208.
111. Muso, E., Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 18:2 (2014 Apr), 286–290.
112. Mabuchi, H., Koizumi, J., Shimizu, M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82 (1998), 1489–1495.
113. Kroon, A.A., Aengevaeren, W.R., van der Werf, T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93 (1996), 1826–1835.
114. Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128:Suppl 5 (2011), S213–256.
115. McGill, H.C. Jr., McMahan, C.A., Starting earlier to prevent heart disease. JAMA 290 (2003), 2320–2322.
116. Steinberg, D., Glass, C.K., Witztum, J.L., Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 118 (2008), 672–677.
117. Domanski, M., Lloyd-Jones, D., Fuster, V., Grundy, S., Can we dramatically reduce the incidence of coronary heart disease?. Nat Rev Cardiol 8 (2011), 721–725.
118. Neil, A., Cooper, J., Betteridge, J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 29 (2008), 2625–2633.
119. Brown, W.V., McNeal, C.J., Gidding, S.S., Screening and management of cardiovascular risk factors in children. J Clin Lipidol 7 (2013), 390–398.
120. Brown, W.V., Wilson, D.P., Freemark, M., Kwiterovich, P.O., The use of lipid-lowering drugs in children. J Clin Lipidol 4 (2010), 449–461.
121. Shah, A.S., Wilson, D.P., Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol 9:5 Suppl (2015), S20–S208.
122. Stone NJ, Robinson JG, Lichtenstein AH et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-2934.
123. Catapano, A.L., Reiner, Z., De Backer, G., et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217 (2011), 3–46.
124. Assmann, G., Schulte, H., Cullen, P., Seedorf, U., Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 37 (2007), 925–932.
125. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148 (1988), 36–69.
126. Expert Dyslipidemia, P., Grundy, S.M., An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 7 (2013), 561–565.
127. Ridker, P.M., Paynter, N.P., Rifai, N., Gaziano, J.M., Cook, N.R., C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008), 2243–2251 2244p following 2251.
128. Ridker, P.M., Buring, J.E., Rifai, N., Cook, N.R., Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007), 611–619.
129. Anum, E.A., Adera, T., Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol 14 (2004), 705–721.
130. Hurley, L.P., Dickinson, L.M., Estacio, R.O., Steiner, J.F., Havranek, E.P., Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. Circ Cardiovasc Qual Outcomes 3 (2010), 181–187.
131. Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
132. Lloyd-Jones, D.M., Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 121 (2010), 1768–1777.
133. Bays, H.E., Adiposopathy is “sick fat” a cardiovascular disease?. J Am Coll Cardiol 57 (2011), 2461–2473.
134. Virani, S.S., Brautbar, A., Davis, B.C., et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 125 (2012), 241–249.
135. Ruiz, J.M., Steffen, P., Smith, T.B., Hispanic mortality paradox: a systematic review and meta-analysis of the longitudinal literature. Am J Public Health 103 (2013), e52–60.
136. Gardin, J.M., Allebban, Z., Wong, N.D., et al. Do differences in subclinical cardiovascular disease in mexican americans versus European americans help explain the Hispanic paradox?. Am J Cardiol 105 (2010), 205–209.
137. Howard, B.V., Lee, E.T., Cowan, L.D., et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 99 (1999), 2389–2395.
138. Howard, B.V., Davis, M.P., Pettitt, D.J., Knowler, W.C., Bennett, P.H., Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians: distributions differing from those of Caucasians. Circulation 68 (1983), 714–724.
139. Nelson, R.G., Sievers, M.L., Knowler, W.C., et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81 (1990), 987–995.
140. Ingelfinger, J.A., Bennett, P.H., Liebow, I.M., Miller, M., Coronary heart disease in the Pima Indians. Electrocardiographic findings and postmortem evidence of myocardial infarction in a population with a high prevalence of diabetes mellitus. Diabetes 25 (1976), 561–565.
141. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
142. Albert, M.A., Glynn, R.J., Fonseca, F.A., et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J 162 (2011), 106–114.e102.
143. Nakamura, H., Arakawa, K., Itakura, H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
144. Yokoyama, M., Origasa, H., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 146 (2003), 613–620.
145. Liao, J.K., Safety and efficacy of statins in Asians. Am J Cardiol 99 (2007), 410–414.
146. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 125 (2012), e2–e220.
147. Yang, Y., Kozloski, M., Change of sex gaps in total and cause-specific mortality over the life span in the United States. Ann Epidemiol 22 (2012), 94–103.
148. Vaidya, D., Becker, D.M., Bittner, V., Mathias, R.A., Ouyang, P., Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: Modelling study of national mortality data. BMJ, 343, 2011, d5170.
149. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
150. Ray, K.K., Seshasai, S.R.K., Erqou, S., et al. Statins and all-cause mortality in high-risk primary prevention: A∖a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170 (2010), 1024–1031.
151. Mora, S., Glynn, R.J., Hsia, J., MacFadyen, J.G., Genest, J., Ridker, P.M., Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121 (2010), 1069–1077.
152. Wenger, N.K., Recognizing pregnancy-associated cardiovascular risk factors. Am J Cardiol 113 (2014), 406–409.
153. Heerwagen, M.J., Miller, M.R., Barbour, L.A., Friedman, J.E., Maternal obesity and fetal metabolic programming: a fertile epigenetic soil. Am J Physiol Regul Integr Comp Physiol 299 (2010), R711–722.
154. Barrett, H.L., Dekker Nitert, M., McIntyre, H.D., Callaway, L.K., Normalizing metabolism in diabetic pregnancy: is it time to target lipids?. Diabetes Care 37 (2014), 1484–1493.
155. Bays, H., Scinta, W., Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease. Curr Med Res Opin, 2015, 1–11 [Epub ahead of print] PubMed PMID: 26331354.
156. Reynolds, R.M., Allan, K.M., Raja, E.A., et al. Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years. BMJ, 347, 2013, f4539.
157. Wild, R.A., Dyslipidemia in PCOS. Steroids 77 (2012), 295–299.
158. Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97 (2012), 28–38.e25.
159. Macut, D., Bjekic-Macut, J., Savic-Radojevic, A., Dyslipidemia and oxidative stress in PCOS. Front Horm Res 40 (2013), 51–63.
160. Lim, S.S., Norman, R.J., Davies, M.J., Moran, L.J., The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 14 (2013), 95–109.
161. Schooling, C.M., Au Yeung, S.L., Freeman, G., Cowling, B.J., The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med, 11, 2013, 57.
162. Raval, A.D., Hunter, T., Stuckey, B., Hart, R.J., Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev, 2011, CD008565.
163. Thurston, R.C., Sutton-Tyrrell, K., Everson-Rose, S.A., Hess, R., Matthews, K.A., Hot flashes and subclinical cardiovascular disease: Findings from the study of Women's Health Across the Nation Heart Study. Circulation 118 (2008), 1234–1240.
164. Kuhn, F.E., Rackley, C.E., Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention. Arch Intern Med 153 (1993), 2626–2636.
165. Derby, C.A., Crawford, S.L., Pasternak, R.C., Sowers, M., Sternfeld, B., Matthews, K.A., Lipid changes during the menopause transition in relation to age and weight: The Study of Women's Health Across the Nation. Am J Epidemiol 169 (2009), 1352–1361.
166. Matthews, K.A., Crawford, S.L., Chae, C.U., et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?. J Am Coll Cardiol 54 (2009), 2366–2373.
167. Bittner, V., Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol 54 (2009), 2374–2375.
168. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273 (1995), 199–208.
169. Cushman, M., Legault, C., Barrett-Connor, E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999), 717–722.
170. Shlipak, M.G., Chaput, L.A., Vittinghoff, E., et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 146 (2003), 870–875.
171. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 (2004), 1701–1712.
172. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002), 321–333.
173. Hulley, S., Grady, D., Bush, T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998), 605–613.
174. Silverberg, M.J., Leyden, W.A., Xu, L., et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr 65 (2014), 160–166.
175. Lichtenstein, K.A., Hart, R.L., Wood, K.C., Bozzette, S., Buchacz, K., Brooks, J.T., HIV Outpatient Study Investigators. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. J Acquir Immune Defic Syndr 69:3 (2015), 306–311.
176. Cohen, J.D., Aspry, K.E., Brown, A.S., et al. Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. J Clin Lipidol 7 (2013), 573–609.
177. World Health Organization. Adherence to long-term therapies: Evidence for Action. 2003. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed October 25, 2015.
178. American College of Preventive Medicine (ACPM) Medican Adhrence: Improving Health Outcomes. A Resource from the American College of Preventive Medicine. 2011. http://www.acpm.org/?MedAdherTT_ClinRef. Accessed October 15, 2015.
179. Peterson, E.D., Ho, P., Barton, M., et al. ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 64 (2014), 2133–2145.
180. Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
181. Ballantyne, C.M., Davidson, M.H., Macdougall, D.E., et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 62 (2013), 1154–1162.
182. Gotto, A.M. Jr., Kher, U., Chatterjee, M.S., et al. Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. J Cardiovasc Pharmacol Ther 19 (2014), 543–549.
183. Gotto, A.M. Jr., Cannon, C.P., Li, X.S., et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 113 (2014), 76–83.
184. Hovingh, G.K., Kastelein, J.J., van Deventer, S.J., et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386 (2015), 452–460.
185. Lise Kjems, Charles Daniel Meyers, Tom Thuren. Diacylglycerol Acyltransferase 1 (DGAT1) Inhibition as a Metabolic Regulator: Clinical Benefits of Pradigastat in Obese Patients With Type 2 Diabetes. Poster 107 presented at 2014 NLA Annual Scientific Sessions, Orlando, Florida, May 1-4, 2014.
186. Vickie Alexander, Trish Novak, Nicholas Viney, John Su, Jennifer Burkey, Walter Singleton, Richard Geary, Isis Pharmaceuticals, Inc, Carlsbad, CA, USA. An Antisense Inhibitor of Apolipoprotein C-III Lowers Fasting Plasma Apolipoprotein C-III and Triglyceride Concentrations in Healthy Volunteers. ACC Moderated Poster Contributions. McCormick Place South, Hall A, Sunday, March 25, 2012, 9:30 a.m.-10:30. E1685JACC March 27, 2012 Volume 59, Issue 13. a.m. Session Title: Prevention: Clinical: Current Research in Lipidology Abstract Category: 9. Prevention: Clinical Presentation Number: 1190-529.
187. Bays, H.E., McKenney, J.M., Dujovne, C.A., et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 92 (2003), 538–543.
188. Bays, H.E., Schwartz, S., Littlejohn, T. 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 96 (2011), 2889–2897.
189. Lu, Z., Kou, W., Du, B., et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101 (2008), 1689–1693.
190. Moriarty, P.M., Roth, E.M., Karns, A., Ye, P., Zhao, S.P., Liao, Y., et al. Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study. J Clin Lipidol 8 (2014), 568–575.
191. Maki KC, Keane WF, Bobotas G. Effects of MAT9001, an Omega-3 Fatty Acid Drug, compared with Eicosapentaenoic Acid Ethyl Esters, on Triglycerides, Lipoprotein Cholesterol, and Releated Variables in Hypertriglyceridemic Subjects. PK/PD Trial Data Presented at the National Lipid Association Scientific Sessions Chicago, IL, USA June 11 - 14, 2015.
192. Norata, G.D., Ballantyne, C.M., Catapano, A.L., New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J 34 (2013), 1783–1789.
193. He, W., Lu, N., Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis. Hepatogastroenterology 62 (2015), 429–434.
194. Hauenschild, A., Bretzel, R.G., Schnell-Kretschmer, H., Kloer, H.U., Hardt, P.D., Ewald, N., Successful treatment of severe hypertriglyceridemia with a formula diet rich in omega-3 fatty acids and medium-chain triglycerides. Ann Nutr Metab 56 (2010), 170–175.
195. Ballantyne, C.M., Neutel, J., Cropp, A., et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115 (2015), 1212–1221.
196. Fitzgerald K, Simon A, White S, et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Results. Abstract. American Heart Association. November 7 - 11. Orlando Florida USA.
197. Tsimikas, S., Viney, N.J., Hughes, S.G., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
198. Donovan J, Manchini M, Sanabria C, Jirousek M. Phase 1 Study of CAT-2054, a Novel Oral Modulator of Sterol Response Element Binding Protein. XVII International Symposium on Atherosclerosis May 23-26 2015. Amsterdam Netherlands.
199. Hegele, R.A., Ginsberg, H.N., Chapman, M.J., et al. European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2 (2014), 655–666.
200. Graham, M.J., Viney, N., Crooke, R., Tsimikas, S., Antisense Inhibition of Apolipoprotein(a) to Lower Plasma Lipoprotein(a) Levels in Humans. J Lipid Res, 2015 [Epub ahead of print].
201. Bays, H.E., Jones, P.H., Jacobson, T.A., et al. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol 10 (2016), 33–57.
202. Bays, H.E., A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. J Clin Lipidol, 2015 [Epub ahead of print].
203. Bays, H., Gaudet, D., Weiss, R., et al. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 100 (2016), 3140–3148.
204. Bays, H.E., Hallén, J., Vige, R., et al. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. J Clin Lipidol 10 (2015), 181–191.
205. Jacobson, T.A., NLA Task Force on Statin Safety–2014 update. J Clin Lipidol 8:3 Suppl (2014), S1–S4.